Magazine Article | May 9, 2017

Where Others Have Failed, Genocea Sees Promise In T-Cell Vaccines

By Mike Goodman, Contributing Writer

Genocea Biosciences is at the forefront of companies harnessing T-cell immunity to conquer the most difficult infectious diseases. Founded in 2006 with antigen discovery technology out of Harvard University, the Cambridge, MA-based company has spent the past decade progressing GEN-003, an HSV-2 (genital herpes) therapeutic vaccine, through the clinic and launching a personalized cancer vaccine franchise that will file its first IND (investigational new drug) this year and enter the clinic in 2018.

THIS CONTENT IS EXCLUSIVELY FOR LIFE SCIENCE LEADER PAID SUBSCRIBERS.
To continue reading this story and receive uninterrupted access to LSL Online and its monthly magazine subscribe to Life Science Leader today!
Already a subscriber? Log in now.